NCT07843147Not yet recruiting
Studies of Blood Glucose and the Microbiome in Tumors and Cysts of the Pancreas
Source: ClinicalTrials.gov · Last updated 25 Sept 2026
Brief summary (registry, in English)
This prospective, single-center observational study investigates whether continuous glucose monitoring (CGM, 14 days) and gut microbiota composition (from a fecal sample) reveal patterns specific to pancreatic cancer, aiming to contribute to earlier detection and better assessment of disease severity. Adult patients under investigation, follow-up, or treatment for benign or malignant pancreatic/periampullary conditions are invited to participate in either or both parts of the study.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 21 Sept 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Oct 2029
- Lead sponsor
- Umeå University
- Diseases
- Pancreatic cancer
- NCT number
- NCT07843147
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Oct 2026 to the primary completion date, 1 Oct 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Adults (≥18 years of age).
- Undergoing clinical investigation, follow-up, or treatment for a pancreatic or periampullary condition (malignant or benign/premalignant, including cystic lesions and pancreatitis).
- Willing and able to provide written informed consent for participation in at least one component of the study (continuous glucose monitoring and/or fecal sample collection).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.